المؤلفون: Vibishan B; Department of Biology, Indian Institute of Science Education and Research (IISER) Pune, Pune, Maharashtra, India. Electronic address: vibishan.b@students.iiserpune.ac.in., B V H; Department of Biology, Indian Institute of Science Education and Research (IISER) Pune, Pune, Maharashtra, India; IISc Mathematics Initiative, Indian Institute of Science, Bangalore, Karnataka, India. Electronic address: bv_harshavardhan@live.com., Dey S; Department of Biology, Indian Institute of Science Education and Research (IISER) Pune, Pune, Maharashtra, India. Electronic address: s.dey@iiserpune.ac.in.

المصدر: Journal of theoretical biology [J Theor Biol] 2024 Jun 21; Vol. 587, pp. 111806. Date of Electronic Publication: 2024 Apr 02.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 0376342 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-8541 (Electronic) Linking ISSN: 00225193 NLM ISO Abbreviation: J Theor Biol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/metabolism , Models, Biological* , Testosterone*/metabolism, Male ; Humans ; Oxygen/metabolism ; Cell Communication/physiology ; Drug Resistance, Neoplasm

المؤلفون: Beshiri ML; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States., Capaldo BJ; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States., Lake R; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States., Ku AT; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States., Burner D; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States., Tice CM; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States., Tran C; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States., Kostas J; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States., Alilin AN; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States., Yin J; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States., Agarwal S; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States., Morris SA; Department of Developmental Biology, Washington University School of Medicine in St Louis, St Louis, MO, United States.; Department of Genetics, Washington University School of Medicine in St Louis, St Louis, MO, United States.; Center of Regenerative Medicine, Washington University School of Medicine in St Louis, St Louis, MO, United States., Karzai FH; Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD, United States., Lotan TL; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Dahut WL; Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD, United States., Sowalsky AG; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States., Kelly K; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States.

المصدر: Stem cells (Dayton, Ohio) [Stem Cells] 2024 Jun 14; Vol. 42 (6), pp. 526-539.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9304532 Publication Model: Print Cited Medium: Internet ISSN: 1549-4918 (Electronic) Linking ISSN: 10665099 NLM ISO Abbreviation: Stem Cells Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/metabolism , Prostatic Neoplasms, Castration-Resistant*/genetics , Cell Lineage*/genetics , Neoplastic Stem Cells*/metabolism , Neoplastic Stem Cells*/pathology , Neoplastic Stem Cells*/drug effects, Male ; Humans ; Animals ; Cell Differentiation ; Phenylthiohydantoin/pharmacology ; Phenylthiohydantoin/analogs & derivatives ; Mice ; Benzamides ; Nitriles

المؤلفون: Shu F; Department of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China., Liu H; Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong, China., Chen X; Department of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China., Liu Y; Department of Pathology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China., Zhou J; Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong, China., Tang L; Department of Pathology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China., Cao W; Department of Pathology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China., Yang S; Department of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China., Long Y; Department of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China., Li R; Department of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China., Wang H; Department of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China., Wang H; Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong, China., Jiang G; Department of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China.

المصدر: Cancer research [Cancer Res] 2024 Jun 14; Vol. 84 (12), pp. 1947-1962.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Epithelial-Mesenchymal Transition* , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/metabolism , Prostatic Neoplasms, Castration-Resistant*/genetics , NFI Transcription Factors*/metabolism , NFI Transcription Factors*/genetics , Up-Regulation* , Gene Expression Regulation, Neoplastic* , Adenosine*/analogs & derivatives , Adenosine*/metabolism, Male ; Humans ; Mice ; Animals ; Cell Line, Tumor ; Mice, Nude ; Receptors, Androgen/metabolism ; Receptors, Androgen/genetics ; Cell Movement ; Neoplasm Metastasis ; Mice, Inbred BALB C ; Xenograft Model Antitumor Assays ; Cell Proliferation

المؤلفون: Zhu Q; Department of Urology, Institute of Urology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan, 610041, P.R. China., Chen J; Department of Urology, Institute of Urology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan, 610041, P.R. China., Liu H; Department of Urology, Institute of Urology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan, 610041, P.R. China., Zhao J; Department of Urology, Institute of Urology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan, 610041, P.R. China., Xu C; Department of Urology, Institute of Urology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan, 610041, P.R. China., Sun G; Department of Urology, Institute of Urology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan, 610041, P.R. China. sungx077@126.com., Zeng H; Department of Urology, Institute of Urology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan, 610041, P.R. China. zengh@scu.edu.cn.

المصدر: BMC cancer [BMC Cancer] 2024 Jun 08; Vol. 24 (1), pp. 706. Date of Electronic Publication: 2024 Jun 08.

نوع المنشور: Journal Article; Systematic Review; Meta-Analysis

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use , Poly(ADP-ribose) Polymerase Inhibitors*/adverse effects , Poly(ADP-ribose) Polymerase Inhibitors*/administration & dosage , Bayes Theorem* , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms, Castration-Resistant*/pathology , Mutation* , Phthalazines*/therapeutic use , Phthalazines*/adverse effects , Phthalazines*/administration & dosage, Humans ; Male ; Network Meta-Analysis ; Piperazines/therapeutic use ; Piperazines/adverse effects ; Piperazines/administration & dosage ; BRCA2 Protein/genetics ; Recombinational DNA Repair/genetics ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Randomized Controlled Trials as Topic ; Progression-Free Survival ; Indoles/therapeutic use ; Indoles/adverse effects ; Indoles/administration & dosage ; BRCA1 Protein/genetics ; Treatment Outcome ; Quinazolines

المؤلفون: Kase AM; Division of Hematology-Oncology, Mayo Clinic Jacksonville, Florida., Gleba J; Cancer Biology Department, Mayo Clinic Jacksonville, Florida., Miller JL; Cancer Biology Department, Mayo Clinic Jacksonville, Florida., Miller E; Cancer Biology Department, Mayo Clinic Jacksonville, Florida., Petit J; Division of Hematology-Oncology, Mayo Clinic Scottsdale, Arizona., Barrett MT; Division of Hematology-Oncology, Mayo Clinic Scottsdale, Arizona., Zhou Y; Division of Hematology-Oncology, Mayo Clinic Scottsdale, Arizona., Parent EE; Radiology Department, Mayo Clinic Jacksonville, Florida., Cai H; Radiology Department, Mayo Clinic Jacksonville, Florida., Knight JA; Cancer Biology Department, Mayo Clinic Jacksonville, Florida., Orme J; Division of Hematology-Oncology, Mayo Clinic Rochester, Minnesota., Reynolds J; Department of Laboratory Medicine and Pathology, Mayo Clinic Jacksonville, Florida., Durham WF; Charles River Discovery Services, Durham, North Carolina., Metz TM; Charles River Discovery Research Services Germany, Freiburg, Germany., Meurice N; Division of Hematology-Oncology, Mayo Clinic Scottsdale, Arizona., Edenfield B; Cancer Biology Department, Mayo Clinic Jacksonville, Florida., Alasonyalilar Demirer A; Cancer Biology Department, Mayo Clinic Jacksonville, Florida., Bilgili A; Cancer Biology Department, Mayo Clinic Jacksonville, Florida., Hickman PG; Cancer Biology Department, Mayo Clinic Jacksonville, Florida., Pawlush ML; Cancer Biology Department, Mayo Clinic Jacksonville, Florida., Marlow L; Cancer Biology Department, Mayo Clinic Jacksonville, Florida., Wickland DP; Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic Jacksonville, Florida., Tan W; Division of Hematology-Oncology, Mayo Clinic Jacksonville, Florida., Copland JA 3rd; Cancer Biology Department, Mayo Clinic Jacksonville, Florida.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2024 Jun 04; Vol. 23 (6), pp. 823-835.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Cyclin-Dependent Kinase 4*/antagonists & inhibitors , Cyclin-Dependent Kinase 6*/antagonists & inhibitors , Xenograft Model Antitumor Assays* , Proto-Oncogene Proteins c-akt*/metabolism , Protein Kinase Inhibitors*/pharmacology , Protein Kinase Inhibitors*/therapeutic use, Humans ; Male ; Animals ; Mice ; Neoplasm Metastasis ; Cell Line, Tumor ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use

المؤلفون: Choudhury AD; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Kwak L; Dana-Farber Cancer Institute, Boston, Massachusetts., Cheung A; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Allaire KM; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Marquez J; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Yang DD; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Tripathi A; City of Hope Comprehensive Cancer Center, Duarte, California., Kilar JM; Dana-Farber Cancer Institute, Boston, Massachusetts., Flynn M; Dana-Farber Cancer Institute, Boston, Massachusetts., Maynard B; Deciphera Pharmaceuticals, Waltham, Massachusetts., Reichel R; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Pace AF; Dana-Farber Cancer Institute, Boston, Massachusetts., Chen BK; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Van Allen EM; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Kilbridge K; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Wei XX; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., McGregor BA; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Pomerantz MM; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Bhatt RS; Harvard Medical School, Boston, Massachusetts.; Beth-Israel Deaconess Medical Center, Boston, Massachusetts., Sweeney CJ; South Australian Immunogenomics Centre, University of Adelaide, Adelaide, Australia., Bubley GJ; Harvard Medical School, Boston, Massachusetts.; Beth-Israel Deaconess Medical Center, Boston, Massachusetts., Jacene HA; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Taplin ME; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Huang FW; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Harshman LC; Dana-Farber Cancer Institute, Boston, Massachusetts., Fong L; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California.

المصدر: Cancer immunology research [Cancer Immunol Res] 2024 Jun 04; Vol. 12 (6), pp. 704-718.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101614637 Publication Model: Print Cited Medium: Internet ISSN: 2326-6074 (Electronic) Linking ISSN: 23266066 NLM ISO Abbreviation: Cancer Immunol Res Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/radiotherapy , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Radium*/therapeutic use, Humans ; Male ; Aged ; Middle Aged ; Aged, 80 and over ; Bone Neoplasms/secondary ; Bone Neoplasms/drug therapy ; CD8-Positive T-Lymphocytes/immunology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

المؤلفون: Neeb A; Institute of Cancer Research, London, United Kingdom., Figueiredo I; Institute of Cancer Research, London, United Kingdom., Bogdan D; Institute of Cancer Research, London, United Kingdom., Cato L; Dana-Farber Cancer Institute, Boston, Massachusetts., Stober J; Karlsruhe Institute of Technology (KIT), Institute for Biological and Chemical Systems - Biological Information Processing (IBCS-BIP), Eggenstein-Leopoldshafen, Germany., Jiménez-Vacas JM; Institute of Cancer Research, London, United Kingdom., Gourain V; Karlsruhe Institute of Technology (KIT), Institute for Biological and Chemical Systems - Biological Information Processing (IBCS-BIP), Eggenstein-Leopoldshafen, Germany., Lee II; Dana-Farber Cancer Institute, Boston, Massachusetts., Seeger R; Karlsruhe Institute of Technology (KIT), Institute for Biological and Chemical Systems - Biological Information Processing (IBCS-BIP), Eggenstein-Leopoldshafen, Germany., Muhle-Goll C; Karlsruhe Institute of Technology (KIT), Institute for Biological Interfaces 4 (IBG-4), Eggenstein-Leopoldshafen, Germany., Gurel B; Institute of Cancer Research, London, United Kingdom., Welti J; Institute of Cancer Research, London, United Kingdom., Nava Rodrigues D; Institute of Cancer Research, London, United Kingdom., Rekowski J; Institute of Cancer Research, London, United Kingdom., Qiu X; Dana-Farber Cancer Institute, Boston, Massachusetts., Jiang Y; Dana-Farber Cancer Institute, Boston, Massachusetts., Di Micco P; Institute of Cancer Research, London, United Kingdom.; MD Anderson Cancer Centre, Houston, Texas., Mateos B; Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology, Barcelona, Spain., Bielskutė S; Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology, Barcelona, Spain., Riisnaes R; Institute of Cancer Research, London, United Kingdom., Ferreira A; Institute of Cancer Research, London, United Kingdom., Miranda S; Institute of Cancer Research, London, United Kingdom., Crespo M; Institute of Cancer Research, London, United Kingdom., Buroni L; Institute of Cancer Research, London, United Kingdom., Ning J; Institute of Cancer Research, London, United Kingdom., Carreira S; Institute of Cancer Research, London, United Kingdom., Bräse S; Karlsruhe Institute of Technology (KIT), Institute of Biological and Chemical Systems - Functional Molecular Systems (IBCS-FMS), Eggenstein-Leopoldshafen, Germany., Jung N; Karlsruhe Institute of Technology (KIT), Institute of Biological and Chemical Systems - Functional Molecular Systems (IBCS-FMS), Eggenstein-Leopoldshafen, Germany., Gräßle S; Karlsruhe Institute of Technology (KIT), Institute of Biological and Chemical Systems - Functional Molecular Systems (IBCS-FMS), Eggenstein-Leopoldshafen, Germany., Swain A; Institute of Cancer Research, London, United Kingdom., Salvatella X; Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology, Barcelona, Spain.; Catalan Institution for Research and Advanced Studies, Barcelona, Spain., Plymate SR; University of Washington, Seattle, Washington.; Geriatrics Research, Education and Clinical Center, VAPSHCS, Seattle, Washington., Al-Lazikani B; MD Anderson Cancer Centre, Houston, Texas., Long HW; Dana-Farber Cancer Institute, Boston, Massachusetts., Yuan W; Institute of Cancer Research, London, United Kingdom., Brown M; Dana-Farber Cancer Institute, Boston, Massachusetts., Cato ACB; Karlsruhe Institute of Technology (KIT), Institute for Biological and Chemical Systems - Biological Information Processing (IBCS-BIP), Eggenstein-Leopoldshafen, Germany., de Bono JS; Institute of Cancer Research, London, United Kingdom.; Royal Marsden NHS Foundation Trust, London, United Kingdom., Sharp A; Institute of Cancer Research, London, United Kingdom.; Royal Marsden NHS Foundation Trust, London, United Kingdom.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2024 Jun 04; Vol. 23 (6), pp. 791-808.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/metabolism , Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Signal Transduction*/drug effects , Disease Progression*, Male ; Humans ; Animals ; Mice ; Receptors, Androgen/metabolism ; Cell Line, Tumor ; DNA-Binding Proteins/metabolism ; DNA-Binding Proteins/genetics ; Transcription Factors/metabolism ; Transcription Factors/genetics ; Cell Proliferation ; Xenograft Model Antitumor Assays ; Gene Expression Regulation, Neoplastic/drug effects

المؤلفون: Kobayashi T; Department of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.; Department of Advanced Informatics for Genetic Diseases, Graduate School of Medicine, Juntendo University, Tokyo, Japan., Nagata M; Department of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan., Hachiya T; Department of Advanced Informatics for Genetic Diseases, Graduate School of Medicine, Juntendo University, Tokyo, Japan., Wakita H; Department of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan., Ikehata Y; Department of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.; Department of Advanced Informatics for Genetic Diseases, Graduate School of Medicine, Juntendo University, Tokyo, Japan., Takahashi K; Department of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan., China T; Department of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan., Shimizu F; Department of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan., Lu J; Department of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan., Jin Y; Department of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan., Lu Y; Department of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan., Ide H; Department of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan., Horie S; Department of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.; Department of Advanced Informatics for Genetic Diseases, Graduate School of Medicine, Juntendo University, Tokyo, Japan.

المصدر: Frontiers in immunology [Front Immunol] 2024 Jun 03; Vol. 15, pp. 1372771. Date of Electronic Publication: 2024 Jun 03 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Myeloid-Derived Suppressor Cells*/immunology , Myeloid-Derived Suppressor Cells*/metabolism , Prostatic Neoplasms, Castration-Resistant*/immunology , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/mortality , Prostatic Neoplasms, Castration-Resistant*/blood, Humans ; Male ; Aged ; Prognosis ; Middle Aged ; Neutrophils/immunology ; Disease Progression ; Aged, 80 and over ; Neoplasm Metastasis

المؤلفون: Jian J; Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.; Department of Urology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China., Wang X; Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China., Zhang J; Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China., Zhou C; Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China., Hou X; Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.; Department of Urology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China., Huang Y; Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China., Hou J; Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.; Department of Urology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China., Lin Y; Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.; Center for Systems Biology, Department of Bioinformatics, School of Biology and Basic Medical Sciences, Soochow University, Suzhou, China., Wei X; Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

المصدر: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Jun 03; Vol. 15, pp. 1360430. Date of Electronic Publication: 2024 Jun 03 (Print Publication: 2024).

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms, Castration-Resistant*/metabolism , Prostatic Neoplasms, Castration-Resistant*/therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Precision Medicine*/methods, Humans ; Male ; Receptors, Androgen/genetics ; Receptors, Androgen/metabolism ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Prognosis

المؤلفون: Swiha M; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.; Nuclear Medicine Division, Department of Medical Imaging, University of Western Ontario, London, Ontario, Canada., Papa N; Garvan Institute of Medical Research, Sydney, New South Wales, Australia., Sabahi Z; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Ayati N; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia; and., John N; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia; and., Pathmanandavel S; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Crumbaker M; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia; and.; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia., Li S; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Agrawal S; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Ayers M; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Hickey A; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Sharma S; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia., Nguyen A; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia; and., Emmett L; Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia; louise.emmett@svha.org.au.; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia; and.

المصدر: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 Jun 03; Vol. 65 (6), pp. 904-908. Date of Electronic Publication: 2024 Jun 03.

نوع المنشور: Journal Article; Comparative Study

بيانات الدورية: Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE

مواضيع طبية MeSH: Positron Emission Tomography Computed Tomography* , Lutetium*/therapeutic use , Prostatic Neoplasms, Castration-Resistant*/diagnostic imaging , Prostatic Neoplasms, Castration-Resistant*/radiotherapy, Humans ; Male ; Treatment Outcome ; Aged ; Middle Aged ; Heterocyclic Compounds, 1-Ring/therapeutic use ; Dipeptides/therapeutic use ; Prostate-Specific Antigen ; Edetic Acid/analogs & derivatives ; Gallium Radioisotopes ; Image Processing, Computer-Assisted ; Gallium Isotopes